Enanta Pharmaceuticals (ENTA) Short Interest Ratio & Short Volume $9.08 -0.34 (-3.61%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Enanta Pharmaceuticals Short Interest DataEnanta Pharmaceuticals (ENTA) has a short interest of 3.44 million shares, representing 17.46% of the float (the number of shares available for trading by the public). This marks a 0.29% increase in short interest from the previous month. The short interest ratio (days to cover) is 22.0, indicating that it would take 22.0 days of the average trading volume of 114,342 shares to cover all short positions.Current Short Interest3,440,000 sharesPrevious Short Interest3,430,000 sharesChange Vs. Previous Month+0.29%Dollar Volume Sold Short$38.68 millionShort Interest Ratio22.0 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares21,190,000 sharesFloat Size19,700,000 sharesShort Percent of Float17.46%Today's Trading Volume181,595 sharesAverage Trading Volume114,342 sharesToday's Volume Vs. Average159% Short Selling Enanta Pharmaceuticals? Sign up to receive the latest short interest report for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENTA Short Interest Over TimeENTA Days to Cover Over TimeENTA Percentage of Float Shorted Over Time Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Enanta Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20243,440,000 shares $38.68 million +0.3%17.5%22 $11.25 10/15/20243,430,000 shares $40.03 million +14.7%17.4%20.7 $11.67 9/30/20242,990,000 shares $30.98 million +2.4%15.2%16.5 $10.36 9/15/20242,920,000 shares $36.30 million +0.3%14.8%16.9 $12.43 8/31/20242,910,000 shares $37.48 million -1.7%14.8%16.7 $12.88 8/15/20242,960,000 shares $36.29 million +5.7%15.0%16 $12.26 Get the Latest News and Ratings for ENTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/31/20242,800,000 shares $41.33 million -3.8%14.2%15.7 $14.76 7/15/20242,910,000 shares $48.13 million -3.3%14.8%16.6 $16.54 6/30/20243,010,000 shares $39.04 million +9.1%15.3%18.3 $12.97 6/15/20242,760,000 shares $35.44 million No Change14.0%15.3 $12.84 5/31/20242,760,000 shares $34.42 million -1.4%14.0%14.7 $12.47 5/15/20242,800,000 shares $37.35 million +0.7%14.2%14.5 $13.34 4/30/20242,780,000 shares $38.20 million +1.5%14.2%12.5 $13.74 4/15/20242,740,000 shares $44.25 million No Change13.9%12 $16.15 3/31/20242,740,000 shares $47.84 million +13.7%13.9%10.4 $17.46 3/15/20242,410,000 shares $34.25 million +15.3%12.3%9.2 $14.21 2/29/20242,090,000 shares $30.03 million -5.4%10.6%8 $14.37 2/15/20242,210,000 shares $29.30 million +20.1%11.2%8.2 $13.26 1/31/20241,840,000 shares $22.36 million +15.7%9.3%6.5 $12.15 1/15/20241,590,000 shares $17.82 million +2.6%8.1%5.4 $11.21 12/31/20231,550,000 shares $14.59 million -13.9%7.9%5.4 $9.41 12/15/20231,800,000 shares $16.81 million +22.5%9.2%6.4 $9.34 11/30/20231,470,000 shares $13.73 million -2.7%7.5%3.4 $9.34 11/15/20231,510,000 shares $13.21 million +12.7%7.7%3.3 $8.75 10/31/20231,340,000 shares $12.09 million +3.9%6.9%3.1 $9.02 10/15/20231,290,000 shares $12.42 million +8.4%6.6%3 $9.63 9/30/20231,190,000 shares $13.29 million -42.0%6.8%2.9 $11.17 9/15/20232,050,000 shares $26.10 million +22.0%10.5%5.2 $12.73 8/31/20231,680,000 shares $24.95 million +16.7%8.6%6 $14.85 8/15/20231,440,000 shares $22.82 million No Change7.4%6.4 $15.85 7/31/20231,440,000 shares $27.32 million +5.9%7.4%6 $18.97 7/15/20231,360,000 shares $26.14 million +14.3%7.0%5.9 $19.22 6/30/20231,190,000 shares $25.47 million +47.3%6.2%5.3 $21.40 6/15/2023808,100 shares $19.54 million +2.3%4.2%3.7 $24.18 5/31/2023789,600 shares $18.54 million +18.2%4.1%3.9 $23.48 5/15/2023667,800 shares $17.28 million -6.4%3.5%3.4 $25.87 4/30/2023713,500 shares $25.36 million -2.4%3.7%3.8 $35.55 4/15/2023730,800 shares $26.70 million +4.8%3.8%4.2 $36.53 3/31/2023697,100 shares $28.19 million -22.6%3.6%3.9 $40.44 3/15/2023900,100 shares $40.06 million +20.0%4.7%5.3 $44.51Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. 2/28/2023750,300 shares $36.39 million -8.4%3.9%4.8 $48.50 2/15/2023819,500 shares $41.12 million -3.8%4.3%5.1 $50.18 1/31/2023851,400 shares $45.45 million +0.4%4.4%5.5 $53.38 1/15/2023847,700 shares $43.62 million -1.6%4.4%5 $51.46 12/30/2022861,500 shares $40.08 million -6.0%4.5%5 $46.52 12/15/2022916,400 shares $40.17 million -11.9%4.8%5.1 $43.84 11/30/20221,040,000 shares $45.54 million +4.2%5.4%5.4 $43.79 11/15/2022998,400 shares $47.14 million -4.0%5.2%4.9 $47.22 10/31/20221,040,000 shares $46.91 million -17.5%5.4%5.1 $45.11 10/15/20221,260,000 shares $59.16 million -2.3%6.5%6 $46.95 9/30/20221,290,000 shares $66.91 million -5.2%6.7%6.4 $51.87 9/15/20221,360,000 shares $78.77 million -8.1%7.0%6.1 $57.92 8/31/20221,480,000 shares $90.10 million -3.3%7.7%6.1 $60.88 8/15/20221,530,000 shares $107.80 million -8.9%7.9%6.1 $70.46 7/31/20221,680,000 shares $92.65 million +3.1%8.7%5.8 $55.15 7/15/20221,630,000 shares $83.64 million -1.8%8.4%5.9 $51.31 6/30/20221,660,000 shares $78.47 million +5.7%8.6%5.8 $47.27 6/15/20221,570,000 shares $62.80 million +6.1%10.7%5.8 $40.00 5/31/20221,480,000 shares $59.10 million +10.5%7.7%6.2 $39.93 5/15/20221,340,000 shares $66.84 million +10.7%6.9%5.5 $49.88 4/30/20221,210,000 shares $77.92 million +9.0%6.3%5.6 $64.40 4/15/20221,110,000 shares $82.42 million -5.9%5.8%5.2 $74.25 3/31/20221,180,000 shares $83.99 million +9.3%6.1%5.4 $71.18 3/15/20221,080,000 shares $70.87 million +21.9%5.6%5.1 $65.62 2/28/2022886,300 shares $62.41 million +13.7%4.6%4 $70.42 2/15/2022779,800 shares $48.51 million -16.5%4.1%3.5 $62.21 1/31/2022933,700 shares $55.48 million +28.6%5.2%4.3 $59.42 1/15/2022726,100 shares $43.57 million +4.0%N/A0 $60.00 12/31/2021697,900 shares $52.19 million -2.4%3.9%3.5 $74.78 12/15/2021715,300 shares $52.22 million +5.4%4.0%3.6 $73.00 11/30/2021678,900 shares $59.93 million -0.3%3.8%3.7 $88.28 11/15/2021681,000 shares $61.21 million -36.9%3.8%4 $89.88 10/29/20211,080,000 shares $92.72 million -32.1%6.1%6.7 $85.85 10/15/20211,590,000 shares $113.64 million -9.7%8.9%10.8 $71.47 9/30/20211,760,000 shares $99.99 million -2.8%9.9%11.8 $56.81 9/15/20211,810,000 shares $106.16 million -7.2%10.1%11.7 $58.65 8/31/20211,950,000 shares $111.54 million -8.9%10.9%12 $57.20 8/13/20212,140,000 shares $100.90 million +4.9%12.0%13.8 $47.15 7/30/20212,040,000 shares $86.19 million +9.1%11.4%13.8 $42.25 7/15/20211,870,000 shares $78.73 million +7.5%10.5%13.5 $42.10 6/30/20211,740,000 shares $76.58 million -7.0%9.8%13.4 $44.01 6/15/20211,870,000 shares $89.57 million -1.6%10.5%15.6 $47.90 5/28/20211,900,000 shares $92.45 million -4.0%10.6%16.9 $48.66 5/14/20211,980,000 shares $99.59 million -2.5%11.1%15.3 $50.30 4/30/20212,030,000 shares $104.24 million -5.1%11.4%14.8 $51.35 4/15/20212,140,000 shares $108.39 million -2.7%12.0%14.6 $50.65 3/31/20212,200,000 shares $105.75 million +1.4%12.3%14.4 $48.07 3/15/20212,170,000 shares $113.25 million +0.5%12.2%13.2 $52.19 2/26/20212,160,000 shares $109.25 million +1.4%12.1%13.1 $50.58 2/12/20212,130,000 shares $114.66 million -9.0%12.0%13.4 $53.83New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 1/29/20212,340,000 shares $107.83 million -1.7%13.2%14.8 $46.08 1/15/20212,380,000 shares $115.05 million -1.2%13.4%14.3 $48.34 12/31/20202,410,000 shares $100.11 million +5.2%13.6%14.3 $41.54 12/15/20202,290,000 shares $97.33 million -3.0%12.9%13.5 $42.50 11/30/20202,360,000 shares $101.24 million -2.9%13.4%13.7 $42.90 11/15/20202,430,000 shares $109.64 million -2.0%13.7%13.9 $45.12 10/30/20202,480,000 shares $108.92 million +15.4%14.0%14.2 $43.92 10/15/20202,150,000 shares $95.78 million +3.4%12.1%12.5 $44.55 9/30/20202,080,000 shares $95.22 million -2.8%11.7%12.7 $45.78 9/15/20202,140,000 shares $100.07 million +5.4%12.1%12.6 $46.76 8/31/20202,030,000 shares $105.95 million +4.1%11.5%12.5 $52.19 8/14/20201,950,000 shares $95.08 million -0.5%11.0%12.2 $48.76 7/31/20201,960,000 shares $89.87 million +3.2%11.1%12.2 $45.85 7/15/20201,900,000 shares $98.17 million +2.2%10.8%12.2 $51.67 6/30/20201,860,000 shares $91.21 million +10.7%10.5%11.7 $49.04 6/15/20201,680,000 shares $81.51 million +5.0%9.5%10.4 $48.52 5/29/20201,600,000 shares $82.56 million +0.6%9.1%8.2 $51.60 5/15/20201,590,000 shares $85.35 million -0.6%9.0%7.4 $53.68 4/30/20201,600,000 shares $78.46 million -8.6%9.1%7.1 $49.04 4/15/20201,750,000 shares $92.09 million -2.8%10.0%7.5 $52.62 3/31/20201,800,000 shares $96.48 million -5.5%10.2%7.2 $53.60 3/13/20201,903,800 shares $100.98 million -1.9%10.8%6.6 $53.04 2/28/20201,940,000 shares $89.10 million -8.5%11.0%9.1 $45.93 2/14/20202,120,000 shares $112.81 million +2.9%12.1%10.3 $53.21 1/31/20202,060,000 shares $105.14 million -10.8%11.8%10.6 $51.04 1/15/20202,310,000 shares $122.01 million -2.9%13.2%12.2 $52.82 12/31/20192,380,000 shares $130.54 million -2.5%13.7%13.8 $54.85 ENTA Short Interest - Frequently Asked Questions What is Enanta Pharmaceuticals' current short interest? Short interest is the volume of Enanta Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 3,440,000 shares of ENTA short. 17.46% of Enanta Pharmaceuticals' shares are currently sold short. Learn More on Enanta Pharmaceuticals' current short interest. What is a good short interest ratio for Enanta Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENTA shares currently have a short interest ratio of 22.0. Learn More on Enanta Pharmaceuticals's short interest ratio. What is a good short interest percentage for Enanta Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.46% of Enanta Pharmaceuticals' floating shares are currently sold short. Is Enanta Pharmaceuticals' short interest increasing or decreasing? Enanta Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 3,440,000 shares, an increase of 0.3% from the previous total of 3,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Enanta Pharmaceuticals' float size? Enanta Pharmaceuticals currently has issued a total of 21,190,000 shares. Some of Enanta Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Enanta Pharmaceuticals currently has a public float of 19,700,000 shares. How does Enanta Pharmaceuticals' short interest compare to its competitors? 17.46% of Enanta Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Enanta Pharmaceuticals: Genfit S.A. (0.13%), Erasca, Inc. (18.80%), Autolus Therapeutics plc (2.70%), Evolus, Inc. (8.58%), Pliant Therapeutics, Inc. (11.87%), Cronos Group Inc. (1.95%), Cullinan Therapeutics, Inc. (23.03%), Prothena Co. plc (13.99%), Replimune Group, Inc. (10.30%), CARGO Therapeutics, Inc. (17.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Enanta Pharmaceuticals stock? Short selling ENTA is an investing strategy that aims to generate trading profit from Enanta Pharmaceuticals as its price is falling. ENTA shares are trading down $0.34 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enanta Pharmaceuticals? A short squeeze for Enanta Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENTA, which in turn drives the price of the stock up even further. How often is Enanta Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENTA, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Genfit Short Interest Data Erasca Short Interest Data Autolus Therapeutics Short Interest Data Evolus Short Interest Data Pliant Therapeutics Short Interest Data Cronos Group Short Interest Data Cullinan Therapeutics Short Interest Data Prothena Short Interest Data Replimune Group Short Interest Data CARGO Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTA Stock Alerts